Quethera Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 3


  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $111M

Quethera General Information


Developer of gene therapy technologies designed to improve the treatment of common blinding eye diseases. The company's technology focuses on the development of therapies that reduce progressive visual loss in glaucoma and other conditions affecting the optic nerve, thereby enabling patients to get an efficient treatment for their eye diseases and recover faster.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
Corporate Office
  • 300 Dashwood Lang Road
  • Bourne Business Park
  • Addlestone KT15 2NX
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Quethera Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 10-Aug-2018 $111M 00000 00000 Completed Generating Revenue
6. Later Stage VC 01-Mar-2018 00000 Completed Startup
5. Later Stage VC 01-Jul-2017 00000 Completed Startup
4. Grant 07-Mar-2016 00000 00000 Completed Startup
3. Seed Round 08-Jul-2015 00000 00000 00.000 Completed Startup
2. Accelerator/Incubator Completed Startup
1. Spin-Off 19-Mar-2013 Completed Startup
To view Quethera’s complete valuation and funding history, request access »

Quethera Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.000
To view Quethera’s complete cap table history, request access »

Quethera Comparisons

HQ Location
Total Raised
Post Valuation
Developer of gene therapy technologies designed to improve the treatment of common blinding eye diseases. The company's
Addlestone, United Kingdom
3 As of 2020
00000 0000-00-00
000000&0 00000

000 00

fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in c
0000 000000000
Ann Arbor, MI
00 As of 0000
0000000000 0 000.00


nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Du
Redcar, United Kingdom
00 As of 0000
000000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Quethera Competitors (41)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI 00 000.00 0000000000 0 000.00
Absolute Antibody Private Equity-Backed Redcar, United Kingdom 00 00.000 000000000000 00.000
Clearside Biomedical Formerly VC-backed Alpharetta, GA 00 00000 00000000 00000
Exonate Venture Capital-Backed Cambridge, United Kingdom 00 00.000 00000000000 00.000
Minoryx Venture Capital-Backed Barcelona, Spain 00 00000 000000 - 000 00000
You’re viewing 5 of 41 competitors. Get the full list »

Quethera Patents

Quethera Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201705484-D0 Genetic construct Inactive 05-Apr-2017 0000000000
ES-2881176-T3 Genetic construction for use in the treatment of neurodegenerative disorder or stroke Active 05-Apr-2017 0000000000
US-20200046850-A1 Genetic construct Inactive 05-Apr-2017 0000000000
JP-2020516244-A Genetic constructs for the treatment of neurodegenerative disorders or stroke Active 05-Apr-2017 000000000 0
AU-2018248651-A1 Genetic construct for use in the treatment of neurodegenerative disorder or stroke Pending 05-Apr-2017 A61K48/005
To view Quethera’s complete patent history, request access »

Quethera Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Quethera Former Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds
Accelerate@Babraham Accelerator/Incubator 000 0000 000000 0
Cambridge Enterprise Corporate Venture Capital Minority 000 0000 000000 0
Discovery Ventures Venture Capital Minority 000 0000 000000 0
Future Planet Capital Venture Capital Minority 000 0000 000000 0
Midven Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

Quethera FAQs

  • When was Quethera founded?

    Quethera was founded in 2013.

  • Who is the founder of Quethera?

    Peter Widdowson Ph.D is the founder of Quethera.

  • Where is Quethera headquartered?

    Quethera is headquartered in Addlestone, United Kingdom.

  • What is the size of Quethera?

    Quethera has 3 total employees.

  • What industry is Quethera in?

    Quethera’s primary industry is Biotechnology.

  • Is Quethera a private or public company?

    Quethera is a Private company.

  • What is the current valuation of Quethera?

    The current valuation of Quethera is 00000.

  • What is Quethera’s current revenue?

    The current revenue for Quethera is 00000.

  • How much funding has Quethera raised over time?

    Quethera has raised $624K.

  • Who are Quethera’s investors?

    Accelerate@Babraham, Cambridge Enterprise, Discovery Ventures, Future Planet Capital, and Midven are 5 of 8 investors who have invested in Quethera.

  • Who are Quethera’s competitors?

    ONL Therapeutics, Absolute Antibody, Clearside Biomedical, Exonate, and Minoryx are some of the 41 competitors of Quethera.

  • When was Quethera acquired?

    Quethera was acquired on 10-Aug-2018.

  • Who acquired Quethera?

    Quethera was acquired by Astellas Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »